Quantcast Fda Green Lights Harvest’s Stem Cell Trial
Search by tag or site Login to my blog ? Start my own blog














TheMoneyBlogs
Home
About
Create your own blog
Contact us
Vote for this blog!

BioHealth Investor

BioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network.

Fda Green Lights Harvest’s Stem Cell Trial

Posted on 05/31/2007 06:21:47 | Link | Post Comment
by Sara Calabro
Med Tech Sentinel



Harvest Technologies, a Plymouth, MA, company that uses stem cells from bone marrow to treat critical limb ischemia, received the go-ahead yesterday from FDA to start a 48-patient trial for the company’s Bone Marrow Aspirate Concentrate (BMAC) System. If all goes as planned, Harvest expects the device to hit the market sometime in 2010.

The BMAC System concentrates a patient’s bone-marrow stem cells in approximately 15 minutes, then injects them into the affected limb to reduce the likelihood of amputation. Critical limb ischemia is a late-stage form of Peripheral Arterial Disease, which involves clogged arteries — commonly in the legs — that can result in toe or feet amputation. The thinking behind the BMAC device is that the injection of stem cells will arrest and possibly reverse the effects of critical limb ischemia.

In a European pilot study of BMAC, 23 patients with ischemic legs who were threatened by amputation were injected with their own bone-marrow stem cells; 16 (70 percent) were able to avoid amputation.

Following yesterday’s IDE approval, Harvest Technologies’ president, Gary Tureski, told The Patriot Ledger that BMAC’s ability to quickly identify and concentrate stem cells that aid in the creation of new blood vessels is what makes it superior to other technologies that use bone-marrow stem cells in a similar way. Harvest’s device is unique, according to Tureski, because a doctor can complete the whole process in one sitting, while other systems rely on shipping the bone marrow off-site for the concentration process, requiring a patient to make more than one trip to the doctor’s office.

“We do it right at the bedside, right at the point of care,’’ Tureski told the paper. ‘‘The whole procedure can be done in less than an hour.’’



RELATED READING:
- Key Stem Cell Patents Revoked
- Stem Cell Stocks Gain On British Study, Geron Gives Some Back
- Osiris: Promising Stem Cell Research, Questionable Management
- At Home Guide to Isolating Amniotic Stem Cells from Placentas!

____________________
Stock Quote or
Examples
ATM Wallstreet - Mon Oct 06, 2008 03:39PM
Made several great trades today. Traded the QID, QQ [read more]
ATM Wallstreet - Sat Oct 04, 2008 10:41PM
When I first started Day Trading I traded anything that [read more]
Morpheus Trading - Thu Oct 02, 2008 08:58AM
NOTE: Please click on the charts below to enlarge them if [read more]

PREMIER SPONSORED LINKS

Most Visited Blogs | Most Popular Blogs | Most Recent Blogs | Contact Us | Terms and conditions | Privacy Policy

The columns, articles, message board posts and any other features provided on TheMoneyBlogs.com are provided for personal finance, education and investment information and are not to be construed as investment advice. Under no circumstances does the information in this content represent a recommendation to buy, sell or hold any security. The views and opinions expressed in an article or column are the author's own and not necessarily those of TheMoneyBlogs.com and there is no implied endorsement by TheMoneyBlogs.com of any advice or trading strategy. The analysts and employees or affiliates of TheMoneyBlogs.com may hold positions in the stocks or industries discussed here. Your use of this and all information contained on TheMoneyBlogs.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

Copyright © 2008 The Connors Group, Inc.